Eli Lilly and

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Eli Lilly and sent this email to their subscribers on October 30, 2024.
October 30, 2024 6:45 AM EDT
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
View this release →
Or click here to view all releases.

Text-only version of this email

Eli Lilly and Company October 30, 2024 6:45 AM EDT Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products View this release → Or click here to view all releases.
Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

More Emails, Deals & Coupons From Eli Lilly and

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 10-Q for Eli Lilly and Company

New Form 10-Q for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Email Offers, Discounts & Promos From Our Top Stores

EXTRA 25% OFF
mmlafleur

EXTRA 25% OFF

3 Colors to Always Avoid Using in Your Home
treehugger

3 Colors to Always Avoid Using in Your Home

Age UK, we need to change how we age
age uk

Age UK, we need to change how we age

🎃 Don't Let this Deal DIE!
ps seasoning and spices

🎃 Don't Let this Deal DIE!

Slightly Buddha , 🤗☕ Cozy Season Is Here!
slightly buddha

Slightly Buddha , 🤗☕ Cozy Season Is Here!

A Cool 13% Off Just For You!
corkcicle

A Cool 13% Off Just For You!

Headlines from Standard-Examiner
standard examiner

Headlines from Standard-Examiner

Watch Now: Proven Strategies to Conquer the Bullwhip Effect
truecommerce

Watch Now: Proven Strategies to Conquer the Bullwhip Effect

Halloween Treat: 20% Off 🎃
sofft

Halloween Treat: 20% Off 🎃

🚨 LAST CHANCE! For BOGO 50% OFF
swanky badger

🚨 LAST CHANCE! For BOGO 50% OFF

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
blueprint medicines

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Up to 30% off ends soon
neiman marcus

Up to 30% off ends soon